Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zavegepant in Children 6 to <12 Years With Migraine
NCT06995729Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- May 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zavegepant in migraine, sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Plasma Concentration and 1 more. Started May 2025; status: recruiting.
02
Drugs
zavegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06995729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995729.